160 related articles for article (PubMed ID: 15226774)
1. Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group).
Elie C; Geay JF; Morcos M; Le Tourneau A; Girre V; Broët P; Marmey B; Chauvenet L; Audouin J; Pujade-Lauraine E; Camilleri-Broët S;
Br J Cancer; 2004 Aug; 91(3):470-5. PubMed ID: 15226774
[TBL] [Abstract][Full Text] [Related]
2. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group.
Camilleri-Broët S; Hardy-Bessard AC; Le Tourneau A; Paraiso D; Levrel O; Leduc B; Bain S; Orfeuvre H; Audouin J; Pujade-Lauraine E;
Ann Oncol; 2004 Jan; 15(1):104-12. PubMed ID: 14679128
[TBL] [Abstract][Full Text] [Related]
3. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer.
de Graeff P; Crijns AP; Ten Hoor KA; Klip HG; Hollema H; Oien K; Bartlett JM; Wisman GB; de Bock GH; de Vries EG; de Jong S; van der Zee AG
Br J Cancer; 2008 Jul; 99(2):341-9. PubMed ID: 18628764
[TBL] [Abstract][Full Text] [Related]
4. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67, and tumor necrosis factor alpha in epithelial ovarian cancer.
Goff BA; Shy K; Greer BE; Muntz HG; Skelly M; Gown AM
Eur J Gynaecol Oncol; 1996; 17(6):487-92. PubMed ID: 8971524
[TBL] [Abstract][Full Text] [Related]
5. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Seidal T
Int J Gynecol Cancer; 2001; 11(2):119-29. PubMed ID: 11328410
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J; Du Bois A; Bentz EK; Kommoss F; Harter P; Huober J; Schmalfeldt B; Burchardi N; Arnold N; Hilpert F
Int J Gynecol Cancer; 2009 Jan; 19(1):109-15. PubMed ID: 19258951
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.
Vergote IB; Jimeno A; Joly F; Katsaros D; Coens C; Despierre E; Marth C; Hall M; Steer CB; Colombo N; Lesoin A; Casado A; Reinthaller A; Green J; Buck M; Ray-Coquard I; Ferrero A; Favier L; Reed NS; Curé H; Pujade-Lauraine E
J Clin Oncol; 2014 Feb; 32(4):320-6. PubMed ID: 24366937
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary.
Wang DP; Konishi I; Koshiyama M; Nanbu Y; Iwai T; Nonogaki H; Mori T; Fujii S
Virchows Arch A Pathol Anat Histopathol; 1992; 421(5):393-400. PubMed ID: 1360720
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
Protopapas A; Diakomanolis E; Bamias A; Milingos S; Markaki S; Papadimitriou C; Dimopoulos AM; Michalas S
Eur J Gynaecol Oncol; 2004; 25(2):225-9. PubMed ID: 15032288
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
11. Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours.
Srirajaskanthan R; Shah T; Watkins J; Marelli L; Khan K; Caplin ME
Oncol Rep; 2010 Apr; 23(4):909-15. PubMed ID: 20204273
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas.
Bouvier-Labit C; Chinot O; Ochi C; Gambarelli D; Dufour H; Figarella-Branger D
Neuropathol Appl Neurobiol; 1998 Oct; 24(5):381-8. PubMed ID: 9821169
[TBL] [Abstract][Full Text] [Related]
14. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis.
Giralt J; de las Heras M; Cerezo L; Eraso A; Hermosilla E; Velez D; Lujan J; Espin E; Rosello J; Majó J; Benavente S; Armengol M; de Torres I;
Radiother Oncol; 2005 Feb; 74(2):101-8. PubMed ID: 15816107
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
Nielsen JS; Jakobsen E; Hølund B; Bertelsen K; Jakobsen A
Int J Gynecol Cancer; 2004; 14(6):1086-96. PubMed ID: 15571614
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor expression has no independent prognostic significance in advanced ovarian cancer.
Baekelandt M; Kristensen GB; Tropé CG; Nesland JM; Holm R
Anticancer Res; 1999; 19(5C):4469-74. PubMed ID: 10650794
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.
Lee CH; Huntsman DG; Cheang MC; Parker RL; Brown L; Hoskins P; Miller D; Gilks CB
Int J Gynecol Pathol; 2005 Apr; 24(2):147-52. PubMed ID: 15782071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
